In patients with stage II-III breast cancer, achievement of pCR to neoadjuvant chemotherapy correlates with improved long-term outcomes, however the predictive value of the standard clinical biomarkers such as ER, PR and HER2 is limited, motivating this study to identify factors mediating response. Here, PGR is linked to breast cancer.